Target effector role of vascular endothelium in the inflammatory response : insights from the clinical trial of anti-TNFα antibody in rheumatoid arthritisPALEOLOG, E.MP. Molecular pathology. 1997, Vol 50, Num 5, pp 225-233, issn 1366-8714Article

The roles of protein kinase C and intracellular Ca²⁺ in the secretion of von Willebrand factor from human vascular endothelial cellsCAREW, M. A; PALEOLOG, E. M; PEARSON, D et al.Biochemical journal (London. 1984). 1992, Vol 286, pp 631-635, issn 0264-6021, 2Article

Circulating endothelial progenitor cells as a link between synovial vascularity and cardiovascular mortality in rheumatoid arthritisAKHAVANI, M. A; LARSEN, H; PALEOLOG, E et al.Scandinavian journal of rheumatology. 2007, Vol 36, Num 2, pp 83-90, issn 0300-9742, 8 p.Article

Adenoviral delivery of soluble VEGF receptor 1 (sFlt-1) abrogates disease activity in murine collagen-induced arthritisAFUWAPE, A. O; FELDMANN, M; PALEOLOG, E. M et al.Gene therapy (Basingstoke). 2003, Vol 10, Num 23, pp 1950-1960, issn 0969-7128, 11 p.Article

Treatment with soluble VEGF receptor reduces disease severity in murine collagen-induced arthritisMIOTLA, J; MACIEWICZ, R; KENDREW, J et al.Laboratory investigation. 2000, Vol 80, Num 8, pp 1195-1205, issn 0023-6837Article

Reduction of chemokine levels and leukocyte traffic to joints by tumor necrosis factor α blockade in patients with rheumatoid arthritisTAYLOR, P. C; PETERS, A. M; PALEOLOG, E et al.Arthritis and rheumatism. 2000, Vol 43, Num 1, pp 38-47, issn 0004-3591Article

Vascular endothelial growth factor in human periodontal diseaseBOOTH, V; YOUNG, S; CRUCHLEY, A et al.Journal of periodontal research. 1998, Vol 33, Num 8, pp 491-499, issn 0022-3484Article

Analysis of cytokine expression in rheumatoid synovium has provided new insights into the pathogenesis of rheumatoid arthritis and new therapeutic opportunitiesFELDMANN, M; BRENNAN, F; BONDESON, J et al.Transplantation proceedings. 2001, Vol 33, Num 3, pp 2085-2086, issn 0041-1345Conference Paper

Anti-tumour necrosis factor specific antibody (infliximab) treatment provides insights into the pathophysiology of rheumatoid arthritisMAINI, R. N; TAYLOR, P. C; PALEOLOG, E et al.Annals of the rheumatic diseases. 1999, Vol 58, pp I56-I60, issn 0003-4967, SUP1Article

Venous Hypoxia: A Poorly Studied Etiological Factor of Varicose VeinsLIM, C. S; GOHEL, M. S; SHEPHERD, A. C et al.Journal of vascular research. 2011, Vol 48, Num 3, pp 185-194, issn 1018-1172, 10 p.Article

What have we learnt from targeted anti-TNF therapy?FELDMANN, M; WILLIAMS, R. O; PALEOLOG, E et al.Annals of the rheumatic diseases. 2010, Vol 69, issn 0003-4967, i97-i99, SUP1Article

Adenovirus-Mediated VEGF Gene Therapy Enhances Venous Thrombus Recanalization and ResolutionMODARAI, B; HUMPHRIES, J; GOSSAGE, J. A et al.Arteriosclerosis, thrombosis, and vascular biology. 2008, Vol 28, Num 10, pp 1753-1759, issn 1079-5642, 7 p.Article

Inhibition of retinal neovascularisation by gene transfer of soluble VEGF receptor sFlt-1BAINBRIDGE, J. W. B; MISTRY, A; DE ALWIS, M et al.Gene therapy (Basingstoke). 2002, Vol 9, Num 5, pp 320-326, issn 0969-7128Article

Is NF-κB a useful therapeutic target in rheumatoid arthritis?FELDMANN, M; ANDREAKOS, E; PALEOLOG, E et al.Annals of the rheumatic diseases. 2002, Vol 61, pp 13-18, issn 0003-4967, 6 p., SUP2Conference Paper

Anti-TNFα therapy is useful in rheumatoid arthritis and Crohn's disease : Analysis of the mechanism of action predicts utility in other diseasesFELDMAN, M; TAYLOR, P; PALEOLOG, E et al.Transplantation proceedings. 1998, Vol 30, Num 8, pp 4126-4127, issn 0041-1345Conference Paper

Monoclonal anti-TNFα antibody as a probe of pathogenesis and therapy of rheumatoid diseaseMAINI, R. N; ELLIOTT, M. J; BRENNAN, F. M et al.Immunological reviews. 1995, Vol 144, pp 195-223, issn 0105-2896Article

New vessels, new approaches : angiogenesis as a therapeutic target in musculoskeletal disordersBALLARA, S. C; MIOTLA, J. M; PALEOLOG, E. M et al.International journal of experimental pathology. 1999, Vol 80, Num 5, pp 235-250, issn 0959-9673Article

Angiogenesis in rheumatoid arthritis : implications for future therapeutic strategiesPALEOLOG, E. M; FAVA, R. A.Springer seminars in immunopathology. 1998, Vol 20, Num 1-2, pp 73-94, issn 0344-4325Article

Differential regulation by cytokines of constitutive and stimulated secretion of von Willebrand factor from endothelial cellsPALEOLOG, E. M; CROSSMAN, D. C; MCVEY, J. H et al.Blood. 1990, Vol 75, Num 3, pp 688-695, issn 0006-4971, 8 p.Article

Deactivation of vascular endothelium by monoclonal anti-tumor necrosis factor α antibody in rheumatoid arthritisPALEOLOG, E. M; HUNT, M; ELLIOTT, M. J et al.Arthritis and rheumatism. 1996, Vol 39, Num 7, pp 1082-1091, issn 0004-3591Article

Effects of tumour necrosis factor and interleukin-1 on von Willebrand factor secretion from human vascular endothelial cellsPALEOLOG, E. M; CAREW, M. A; PEARSON, J. D et al.International journal of radiation biology (Print). 1991, Vol 60, Num 1-2, pp 279-285, issn 0955-3002Conference Paper

Modulation of angiogenic vascular endothelial growth factor by tumor necrosis factor α and interleukin-1 in rheumatoid arthritisPALEOLOG, E. M; YOUNG, S; STARK, A. C et al.Arthritis and rheumatism. 1998, Vol 41, Num 7, pp 1258-1265, issn 0004-3591Article

In vitro target validation and in vivo efficacy of p38 MAP kinase inhibition in established chronic collagen-induced arthritis model: a pre-clinical studyTRIANTAPHYLLOPOULOS, K; MADDEN, L; RIOJA, I et al.Clinical and experimental rheumatology (Testo stampato). 2010, Vol 28, Num 2, pp 176-185, issn 0392-856X, 10 p.Article

Von Willebrand factor is an acute phase reactant in manPOTTINGER, B. E; READ, R. C; PALEOLOG, E. M et al.Thrombosis research. 1989, Vol 53, Num 4, pp 387-394, issn 0049-3848Article

Vascular endothelial growth factor in normal human salivary glands and saliva : A possible role in the maintenance of mucosal homeostasisTAICHMAN, N. S; CRUCHLEY, A. T; FLETCHER, L. M et al.Laboratory investigation. 1998, Vol 78, Num 7, pp 869-875, issn 0023-6837Article